Biocon Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BIOCON.NS | REGN | 068270.KS | TECH | ROIV | RPRX | |
|---|---|---|---|---|---|---|
| Market cap | 571.90B | 81.41B | 44.24T | 11.38B | 24.22B | 35.22B |
| P/E (TTM) | 103.3 | 19.6 | — | 62.6 | — | 32.4 |
| Forward P/E | 31.9 | 12.8 | — | 31.4 | -19.5 | 10.5 |
| Price/book | 1.7 | 2.5 | — | 5.4 | 5.7 | 4.0 |
| Dividend yield | 0.14% | 0.48% | 0.37% | 0.44% | — | 1.54% |
| 1-year change | −1.17% | +37.10% | +15.02% | +16.04% | +89.01% | +66.42% |
| Today | −0.80% | −0.70% | +6.53% | +0.07% | −1.50% | +2.25% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All BIOCON.NS news ›Biocon gets launch clarity for breast cancer biosimilar after Genentech deal
Biocon has secured a clearer timeline for commercialising its pertuzumab biosimilar, Pebrilzo, after reaching a global patent settlement and licensing agreement with Genentech, resolving disputes that had clouded its market entry plans.…
Biocon inks global patent settlement pact with Genentech for breast cancer drug Pebrilzo
Biocon Ltd on Wednesday said it has entered into a global settlement and license agreement with Genentech for breast cancer drug Pebrilzo, its biosimilar to the reference product Perjeta (Pertuzumab). The patent settlement agreement…
Biocon settles patent dispute with Genentech over breast cancer drug Pebrilzo; US launch in 2028
Biocon Ltd on Wednesday said it has entered into a global settlement and license agreement with Genentech for breast cancer drug Pebrilzo, its biosimilar to the reference product Perjeta (Pertuzumab). The patent settlement agreement…
Genentech Drops Lawsuit Against Biocon Over Perjeta Biosimilar
Bloomberg Law News Genentech Inc. voluntarily dismissed claims that Biocon Biologics Inc. infringed 28 patents covering the blockbuster Perjeta treatment for a type of metastatic breast cancer. Genentech and parent Hoffmann-La Roche Inc.…
Biocon Secures Earliest Licensed Launch Dates for Pebrilzo® (bPertuzumab) Following Global Patent Settlement with Genentech
EquityBulls Biocon Secures Earliest Licensed Launch Dates for Pebrilzo® (bPertuzumab) Following Global Patent Settlement with Genentech Biocon Limited (BSE: 532523, NSE: BIOCON) has entered into a global settlement and license agreement…
Biocon Secures Global Patent Settlement With Genentech, Sets 2027 EU Launch for Perjeta Biosimilar
New Delhi: Biocon Limited has entered into a global patent settlement and licence agreement with Genentech, securing launch timelines for Pebrilzo, its biosimilar to Perjeta (pertuzumab), a reference medicine used to treat HER2-positive…
India Must Move from Volume to Value in Pharma, says Biocon Chief Kiran Shaw
New Delhi: India must move beyond its success in generic medicines and build an innovation-led pharmaceutical industry by strengthening research, speeding up regulatory approvals and consistently investing in new drug development, Biocon…
Biocon Limited: Relative Strength Chart - Stock NSE India S.E.
Compare Biocon Limited with the company of your choice via a Relative Strength chart. Real-time BIOCON price, NSE India S.E. stock exchange Relative Strength Chart Biocon Limited Biotechnology & Medical Research All financial news and data…
Transcript : Biocon Limited, Q1 2027 Earnings Call, Aug 06, 2026
Presentation Operator MessageOperator Ladies and gentlemen, good day, and welcome to Biocon Limited Q1 FY '27 Earnings Conference Call. [Operator Instructions] Please note that this meeting is Transcript : Biocon Limited, Q1 2027 Earnings…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com8
-
medicaldialogues.in4
-
tradingview.com4
-
thehindubusinessline.com3
-
business-standard.com2
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 50 articles, not a forecast.